Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age50+
SponsorAnhui Medical University
About this trial
The pathological-omics and imaging-omics in this study are combined to construct an artificial intelligence (AI) model that can predict whether high-risk prostate cancer patients may have lymph node metastasis. The model determines whether the patient has lymph node metastasis based on the MRI results and the pathological section image information of the case combined with clinical data before radical resection of the prostate. This study is a multicenter, prospective clinical study to verify the model's ability to predict whether high-risk prostate cancer patients may have lymph node metastasis.
Eligibility criteria
Qualifiers
Age ≥ 50 years
Patients must have histologically or cytologically confirmed prostate adenocarcinoma
PSA ≥ 20ng/ml or Gleason ≥ 8
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2
Disqualifiers
Patients with contraindications to MRI examination, such as metal implants in the body, claustrophobia, etc.
Patients with any missing baseline clinical and pathological information
Patients with a clear history of neurological and psychiatric disorders, such as dementia, epilepsy, or seizures
In the judgment of the investigator, there are serious concomitant diseases that endanger the safety of the subjects or affect the subjects' completion of this study (such as severe diabetes, thyroid disease, and mental illness, etc.), or factors that affect the safety of the patients or affect the patients' provision of informed consent (including laboratory abnormalities), or any psychological, family, sociological or geographical conditions that affect the study plan and follow-up plan
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov